SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Emergent BioSolutions Inc.

(Last)

(First)

(Middle)

400 PROFESSIONAL DRIVE, SUITE 400

(Street)

GAITHERSBURG

20879

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/23/2019

3. Issuer Name and Ticker or Trading Symbol
Emergent BioSolutions Inc. [ EBS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director		10% Owner
Officer (give title below)	X	Other (specify below)
		Sean Kirk, EVP, Manufacturing

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	13,604⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Options (Right to Buy)	⁽²⁾	02/28/2023	Common Stock	3,135	$30.86	D
Stock Options (Right to Buy)	⁽²⁾	02/27/2024	Common Stock	7,293	$30.63	D
Stock Options (Right to Buy)	⁽²⁾	02/26/2025	Common Stock	6,044	$49.64	D
Stock Options (Right to Buy)	⁽²⁾	02/25/2026	Common Stock	5,124	$61.01	D
Stock Options (Right to Buy)	⁽²⁾	03/31/2026	Common Stock	1,424	$50.52	D

Explanation of Responses:

1. Consists of 2,933 shares, as well as 1,424 unvested PSUs and 9,247 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU and each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.

2. Vests in three equal annual installments beginning on the day prior to the anniversary date of the grant.

Remarks:

Exhibit List: Exhibit-24.1 Power of Attorney

	/s/ S. Scott Lieberman, Attorney-in-fact	06/03/2019
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.